Roivant Sciences Ltd.
ROIV
Rankning i aktier
#978
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Aktiekurs
$33.73
Senast synkroniserad: 2026-07-31
Marknadsvärde
$24.37B
Förändring (1 dag)
-2.28%
Förändring (1 år)
90.15%
Land
GB
Handel Roivant Sciences Ltd. (ROIV)
Kategori
Healthcare
Utdelningsavkastning för Roivant Sciences Ltd. (ROIV)
Utdelningsavkastningen (TTM) för Roivant Sciences Ltd. (aktiesymbol: ROIV) per 2024-03-31 är: 0.07%
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.01%
Genomsnittlig utdelningsavkastning de senaste 5 åren: 0.01%
Historik för utdelningsavkastning för Roivant Sciences Ltd. (ROIV) från 2020 till 2026
Utdelningsavkastning i slutet av varje år (TTM)
| År | Utdelningsavkastning | Ändra |
|---|---|---|
| 2026 (TTM) | 0.00% | -100.00% |
| 2025 | 0.00% | -100.00% |
| 2024 | 0.07% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | 0.00% |
| 2021 | 0.00% | 0.00% |
| 2020 | 0.00% | 0.00% |
Utdelningsavkastning (TTM) för liknande företag eller konkurrenter
| Företag | Utdelningsavkastning | Land |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
CH
|
|
| 0.00% |
NL
|
